journal article·2022-10-19Open access

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges

Deniz Can Guven, Taha Koray Sahin, Alessandro Rizzo, Angela Dalia Ricci, Sercan Aksoy, Kazim Sahin

Applied Sciences· Volume 12· Issue 20

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and reshaped medical oncology practice over the past decade. However, despite unprecedented and durable clinical responses, most patients eventually fail to respond to ICI therapy due to primary or acquired resistance. There is a great need for complementary alternative medicine, such as botanicals and nutritional supplements, because of their capability to modulate a myriad of molecular mechanisms to prevent immunotherapy resistance and reduce its adverse effects. Mounting evidence suggests that phytochemicals, biologically active compounds derived from plants, can favorably regulate key signaling pathways involved in tumor development and progression. In addition, phytochemicals have been found to exert anticancer effects by altering the expression of checkpoint inhibitors of the immune response. The immunomodulatory activity of phytochemicals in the tumor microenvironment has recently received immense interest. Based on these immunomodulatory activities, phytochemicals could be candidates for combination with ICIs in future clinical studies. The current review focuses on the available evidence for combining phytochemicals with a discussion on the promising opportunities to enhance the efficacy of immune checkpoint inhibitors and potential challenges resulting from these combinations.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Mechanisms and Therapy · Berberine and alkaloids research · Piperaceae Chemical and Biological Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Oncology, Faculty of Medicine, University of Hacettepe, Ankara 06230, Turkey

Department of Internal Medicine, Faculty of Medicine, University of Hacettepe, Ankara 06230, Turkey

Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, IRCCS Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy

Medical Oncology Unit, National Institute of Gastroenterology, “Saverio de Bellis” Research Hospital, Castellana Grotte, 70013 Bari, Italy

Department of Animal Nutrition, Faculty of Veterinary Medicine, Firat University, Elazig 23200, Turkey

References (100+)

Show source-provided references
1. Immune checkpoint inhibitors: Recent progress and potential biomarkers10.1038/s12276-018-0191-1 ↗
2. Combination therapy: Future directions of immunotherapy in small cell lung cancer10.1016/j.tranon.2020.100889 ↗
3. Immunotherapy Combined or Sequenced with Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives10.1093/jnci/djv414 ↗
4. Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer10.1016/j.omto.2019.02.001 ↗
5. Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 12.10.3390/cancers12030738 ↗
6. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics10.1186/s13045-019-0779-5 ↗
7. Mechanisms of Cancer Resistance to Immunotherapy10.3389/fonc.2020.01290 ↗
8. Azqueta, A., and Collins, A. (2016). Polyphenols and DNA Damage: A Mixed Blessing. Nutrients, 8.10.3390/nu8120785 ↗
9. Antioxidant Phytochemicals for the Prevention and Treatment of Chronic Diseases10.3390/molecules201219753 ↗
10. Sahin, T.K., Bilir, B., and Kucuk, O. (2021). Modulation of inflammation by phytochemicals to enhance efficacy and reduce toxicity of cancer chemotherapy. Crit. Rev. Food Sci. Nutr., 1–15.10.1080/10408398.2021.1976721 ↗
11. Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy10.1007/978-1-0716-0266-9_14 ↗
12. Exploring the multifocal role of phytochemicals as immunomodulators10.1016/j.biopha.2020.110959 ↗
13. Phytochemicals Approach for Developing Cancer Immunotherapeutics10.3389/fphar.2017.00386 ↗
14. Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients10.1016/j.neo.2017.08.004 ↗
15. Molecular insights into phytochemicals-driven break function in tumor microenvironment10.1111/jfbc.13824 ↗
16. Li, W., Kim, T.I., Kim, J.H., and Chung, H.-S. (2019). Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds. Molecules, 24.10.3390/molecules24224062 ↗
17. Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer10.1016/j.intimp.2021.107395 ↗
18. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway10.1056/NEJMra1514296 ↗
19. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma10.1016/j.apsb.2021.03.010 ↗
20. Chemoprotective role of an extract of the heart of the Phoenix dactylifera tree on adriamycin-induced cardiotoxicity and nephrotoxicity by regulating apoptosis, oxidative stress and PD-1 suppression10.1016/j.fct.2019.111045 ↗
21. Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma10.1016/j.archoralbio.2018.04.015 ↗
22. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT310.1016/j.phrs.2018.08.004 ↗
23. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects10.1186/s13046-018-0929-6 ↗
24. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells10.1016/j.intimp.2019.105824 ↗
25. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer10.1016/j.canlet.2021.05.019 ↗
26. STAT1 and STAT3 in tumorigenesis: A matter of balance10.4161/jkst.20045 ↗
27. Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer10.2147/OTT.S130653 ↗
28. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo10.1002/jcp.29580 ↗
29. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma10.1016/j.lfs.2021.119359 ↗
30. Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer10.1080/10717544.2021.1921077 ↗
31. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT310.1111/cas.14675 ↗
32. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer10.1016/j.phymed.2021.153758 ↗
33. Kang, D.Y., Sp, N., Jo, E.S., Rugamba, A., Hong, D.Y., Lee, H.G., Yoo, J.S., Liu, Q., Jang, K.J., and Yang, Y.M. (2020). The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells. Cancers, 12.10.3390/cancers12030727 ↗
34. An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma10.3389/fimmu.2020.584959 ↗
35. Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells10.1186/s13027-019-0247-4 ↗
36. Liu, X., Wang, L., Jing, N., Jiang, G., and Liu, Z. (2020). Biostimulating Gut Microbiome with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine Colon Cancer. Microorganisms, 8.10.3390/microorganisms8020175 ↗
37. Icaritin inhibits PD-L1 expression by Targeting Protein IκB Kinase α10.1002/eji.202048905 ↗
38. Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer10.1124/jpet.118.254359 ↗
39. Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells10.1186/s12935-019-0789-y ↗
40. Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses10.1007/s00262-019-02338-4 ↗
41. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota10.1038/s41419-018-1099-3 ↗
42. Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver10.20892/j.issn.2095-3941.2020.0278 ↗
43. Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF-κB signaling
44. Synergistic anti-liver cancer effects of curcumin and total ginsenosides10.4251/wjgo.v12.i10.1091 ↗
45. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity10.18632/aging.102646 ↗
46. Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells10.1007/s00432-021-03510-z ↗
47. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells10.1016/j.canlet.2016.06.023 ↗
48. Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model10.3389/fimmu.2020.598556 ↗
49. Rawangkan, A., Wongsirisin, P., Namiki, K., Iida, K., Kobayashi, Y., Shimizu, Y., Fujiki, H., and Suganuma, M. (2018). Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth. Molecules, 23.10.3390/molecules23082071 ↗
50. Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism10.1016/j.abb.2020.108479 ↗
51. Rugamba, A., Kang, D.Y., Sp, N., Jo, E.S., Lee, J.M., Bae, S.W., and Jang, K.J. (2021). Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells. Cells, 10.10.3390/cells10071632 ↗
52. Wudtiwai, B., Makeudom, A., Krisanaprakornkit, S., Pothacharoen, P., and Kongtawelert, P. (2021). Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells. Molecules, 26.10.3390/molecules26175345 ↗
53. Baicalin triggers apoptosis, inhibits migration, and enhances anti-tumor immunity in colorectal cancer via TLR4/NF-κB signaling pathway10.1111/jfbc.13703 ↗
54. Licochalcone A inhibits proliferation and promotes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK pathways10.1016/j.jep.2021.113989 ↗
55. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice10.1002/eji.201948225 ↗
56. Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico10.1038/s41598-019-47903-0 ↗
57. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells10.1016/j.bcp.2022.114940 ↗
58. Kim, J.H., Kim, Y.S., Choi, J.-G., Li, W., Lee, E.J., Park, J.-W., Song, J., and Chung, H.-S. (2020). Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro. Int. J. Mol. Sci., 21.10.3390/ijms21093239 ↗
59. Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells10.1016/j.fct.2019.05.045 ↗
60. Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines10.1007/s11060-019-03193-0 ↗
61. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients10.1016/j.biopha.2020.111057 ↗
62. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells10.1016/j.phrs.2020.104727 ↗
63. Bedi, D., Henderson, H.J., Manne, U., and Samuel, T. (2019). Camptothecin induces PD-L1 and immunomodulatory cytokines in colon cancer cells. Medicines, 6.10.3390/medicines6020051 ↗
64. Triorganotin Isothiocyanates Affect Migration and Immune Check-point Receptors in Human Triple-negative Breast Carcinoma MDA-MB-231 Cells10.21873/anticanres.13670 ↗
65. The extracts of Astragalus membranaceus overcome tumor immune tolerance by inhibition of tumor programmed cell death protein ligand-1 expression10.7150/ijms.42978 ↗
66. Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma10.1007/s10517-020-04891-w ↗
67. Black raspberry extract inhibits regulatory T-cell activity in a murine model of head and neck squamous cell carcinoma chemoprevention10.3389/fimmu.2022.932742 ↗
68. The role of gut microbiota in immune homeostasis and autoimmunity10.4161/gmic.19320 ↗
69. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors10.1126/science.aan3706 ↗
70. Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab10.1200/JCO.2018.36.15_suppl.4519 ↗
71. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients10.3748/wjg.v27.i42.7340 ↗
72. Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer10.1186/s13568-022-01428-4 ↗
73. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial10.1038/s41591-022-01694-6 ↗
74. A Soluble Fiber Diet Increases Bacteroides fragilis Group Abundance and Immunoglobulin A Production in the Gut10.1128/AEM.00405-20 ↗
75. Nondigestible Fructans Alter Gastrointestinal Barrier Function, Gene Expression, Histomorphology, and the Microbiota Profiles of Diet-Induced Obese C57BL/6J Mice10.3945/jn.115.227504 ↗
76. Growth of selected probiotic bacterial strains with fructans from Nendran banana and garlic10.1016/j.lwt.2017.03.059 ↗
77. Gut microbiota and cancer immunotherapy: Prognostic and therapeutic implications10.2217/fon-2019-0783 ↗
78. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota10.1126/science.aad1329 ↗
79. Daily Supplementation with Fresh Angelica keiskei Juice Alleviates High-Fat Diet-Induced Obesity in Mice by Modulating Gut Microbiota Composition10.1002/mnfr.201900248 ↗
80. González, S., Salazar, N., Ruiz-Saavedra, S., Gómez-Martín, M., de Los Reyes-Gavilán, C.G., and Gueimonde, M. (2020). Long-Term Coffee Consumption is Associated with Fecal Microbial Composition in Humans. Nutrients, 12.10.3390/nu12051287 ↗
81. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy10.1126/science.aac4255 ↗
82. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity10.1039/c3fo60630a ↗
83. Plant Foods and Herbal Sources of Resveratrol10.1021/jf0112973 ↗
84. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis10.1038/ncomms10391 ↗
85. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab10.1093/annonc/mdx108 ↗
86. Chemoprevention of colorectal cancer by black raspberry anthocyanins involved the modulation of gut microbiota and SFRP2 demethylation10.1093/carcin/bgy009 ↗
87. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients10.1126/science.aan4236 ↗
88. The inhibitory effect of polyphenols on human gut microbiota
89. Dietary Black Raspberries Impact the Colonic Microbiome and Phytochemical Metabolites in Mice10.1002/mnfr.201800636 ↗
90. Food as medicine: Potential therapeutic tendencies of plant derived polyphenolic compounds
91. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients10.1126/science.aao3290 ↗
92. Interaction of dietary polyphenols and gut microbiota: Microbial metabolism of polyphenols, influence on the gut microbiota, and implications on host health10.1002/fft2.25 ↗
93. Triggering Akkermansia with dietary polyphenols: A new weapon to combat the metabolic syndrome?10.1080/19490976.2016.1142036 ↗
94. Obesity treatment by epigallocatechin-3-gallate-regulated bile acid signaling and its enriched Akkermansia muciniphila
95. Dietary fiber and prebiotics and the gastrointestinal microbiota10.1080/19490976.2017.1290756 ↗
96. Gut microbiome and immunotherapy response in melanoma patients10.1200/JCO.2018.36.15_suppl.9575 ↗
97. Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies10.1200/JCO.2018.36.15_suppl.3011 ↗
98. Deciphering the Human Gut Microbiome of Urolithin Metabotypes: Association with Enterotypes and Potential Cardiometabolic Health Implications10.1002/mnfr.201800958 ↗
99. Gut Bacterial Metabolite Urolithin A (UA) Mitigates Ca2+ Entry in T Cells by Regulating miR-10a-5p10.3389/fimmu.2019.01737 ↗
100. Association of microbiome and plasma cytokine dynamics to nivolumab response in metastatic renal cell carcinoma (mRCC)10.1200/JCO.2018.36.6_suppl.656 ↗